Results 31 to 40 of about 14,298 (222)

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

Journal of Hematology & Oncology, 2018
Background Chimeric antigen receptor (CAR)-engineered T cells have demonstrated promising clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T cell therapy in the treatment of other solid tumors has been limited.
Jiayi Yu, Xiaowen Wu, Junya Yan, Huan Yu, Longwen Xu, Zhihong Chi, Xinan Sheng, Lu Si, Chuanliang Cui, Jie Dai, Meng Ma, Tianxiao Xu, Yan Kong, Jun Guo   +13 more
doaj   +1 more source

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

Journal for ImmunoTherapy of Cancer, 2021
Background The addition of monoclonal antibody therapy against GD2 to the treatment of high-risk neuroblastoma led to improved responses in patients. Nevertheless, administration of GD2 antibodies against neuroblastoma is associated with therapy-limiting
Stefan Nierkens, Niels Eijkelkamp, Maaike Nederend, Jeanette Leusen, Mitchell Evers, Marjolein Stip, Kaylee Keller, Hanneke Willemen, Marco Jansen, Chilam Chan, Kevin Budding, Thomas Valerius, Friederike Meyer-Wentrup   +12 more
doaj   +1 more source

Neuromuscular synaptic transmission in aged ganglioside-deficient mice [PDF]

, 2011
Gangliosides are sialylated glycosphingolipids that are present in high density on neuronal membranes, especially at synapses, where they are assumed to play functional or modulating roles.
Todorov, Boyan, Furukawa, Keiko, Furukawa, K., Plomp, J.J., Verschuuren, Jan J., Willison, H.J., Furukawa, Koichi, Plomp, Jaap J., Jacobs, B.C., Todorov, B., Willison, Hugh J., Jacobs, Bart C., Zitman, F.M.P., Verschuuren, J.J., Zitman, Femke M.P.   +14 more
core   +1 more source

GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction

Translational Oncology, 2021
A novel disialoganglioside 2 (GD2)-specific chimeric antigen receptor (CAR)-modified T cell therapy against retinoblastoma (RB) were generated. GD2-CAR consists of a single-chain variable fragment (scFv) derived from a monoclonal antibody, hu3F8, that is
Jatuporn Sujjitjoon, Elias Sayour, Shih-Ting Tsao, Mongkol Uiprasertkul, Kleebsabai Sanpakit, Jassada Buaboonnam, Pa-thai Yenchitsomanus, La-ongsri Atchaneeyasakul, Lung-Ji Chang   +8 more
doaj   +1 more source

Differential roles of gangliosides in malignant properties of melanomas. [PDF]

PLoS ONE, 2018
Ganglioside GD3 is widely expressed in human malignant melanomas, and has been reported to be involved in the increased cell proliferation and invasion.
Yuhsuke Ohmi, Mariko Kambe, Yuki Ohkawa, Kazunori Hamamura, Orie Tajima, Rika Takeuchi, Koichi Furukawa, Keiko Furukawa   +7 more
doaj   +1 more source

Neuromuscular synaptic function in mice lacking major subsets of gangliosides [PDF]

, 2008
Gangliosides are a family of sialylated glycosphingolipids enriched in the outer leaflet of neuronal membranes, in particular at synapses. Therefore, they have been hypothesized to play a functional role in synaptic transmission.
Furukawa, K., Plomp, J.J., Willison, H.J., Willison, HJ, Verschuuren, JJ, Todorov, B, Furukawa, K, Jacobs, B.C., Zitman, FMP, Todorov, B., Zitman, F.M.P., Verschuuren, J.J., Plomp, JJ   +12 more
core   +1 more source

Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin

Pharmaceutics, 2022
Disialoganglioside (GD2) is a subtype of glycolipids that is highly expressed in tumors of neuroectodermal origins, such as neuroblastoma and osteosarcoma.
Fuyuki F. Inagaki, Takuya Kato, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi   +8 more
doaj   +1 more source

IMMU-55. GD2 IS A MACROPHAGE CHECKPOINT MOLECULE AND COMBINED GD2/CD47 BLOCKADE RESULTS IN SYNERGISTIC EFFECTS AGAINST GD2 POSITIVE MALIGNANCIES [PDF]

Neuro-Oncology, 2020
Abstract GD2 is a disialoganglioside expressed on a variety of tumors including DIPG, neuroblastoma and osteosarcoma. Anti-GD2 antibodies have demonstrated some success in neuroblastoma and they have either not proven to be effective or have not been evaluated in other GD2 positive malignancies. CD47 is the dominant “Don’t Eat Me” signal
Johanna Theruvath, Christopher Mount, Michelle Monje, Crystal Mackall, Robbie Majzner   +4 more
openaire   +1 more source

GD2 synthase [PDF]

Cancer, 2001
Neuroblastomas (NBs) almost ubiquitously express the ganglioside GD2. GD2 synthesis is dependent on the key enzyme GD2 synthase. Thus, GD2 synthase transcript may prove to be a potential molecular marker of NB.Seventy-seven NB tumor tissues of all stages, 5 NB cell lines, and 26 normal bone marrows (BMs) and peripheral blood (PBL) samples, as well as ...
M S, Lo Piccolo, N K, Cheung, I Y, Cheung   +2 more
openaire   +2 more sources

Upregulation of Ganglioside GD2 Synthase (GD2S), as a New Putative Cancer Stem Cell Marker in Breast Carcinomas [PDF]

Medical Journal of The Islamic Republic of Iran, 2021
Background: GD2 synthase (GD2S) is the key enzyme required for ganglioside GD2 synthesis. It is commonly expressed in normal tissues and various cancers. Ganglioside GD2 is identified as a breast cancer stem cells (BCSCs) marker that promotes tumorigenesis.
Mansoori, Maryam, Mirzaei, Alireza, Abdi Rad, Isa, Mahmodlou, Rahim, Mansouri, Fatemeh, Saeednejad Zanjani, Leili, Asadi- Lari, Zeynab, Madjd, Zahra   +7 more
openaire   +2 more sources